Baidu
map

内分泌科指南

订阅

MedSci主页 / 所有栏目 / 内分泌科指南

2020 JES临床指南：自身免疫性和IgG4相关性垂体炎的诊断和治疗

2020-02-07 日本内分泌学会 Endocr J. 2020 Feb 7.

自身免疫性垂体炎IgG4相关性垂体炎

2020年2月，日本内分泌学会(JES)发布了自身免疫性和IgG4相关性垂体炎的诊断和治疗指南，吹体验常伴有垂体功能障碍，依据病因、组织学和炎症在垂体中的部位可分为几种亚型。本文主要针对自身免疫性和IgG4相关性垂体炎的诊断和治疗提供指导建议。

中文标题：

2020 JES临床指南：自身免疫性和IgG4相关性垂体炎的诊断和治疗

英文标题：

Diagnosis and treatment of autoimmune and IgG4- related hypophysitis: clinical guidelines of the Japan Endocrine Society

发布机构：

日本内分泌学会

发布日期：

2020-02-07

简要介绍：

2020年2月，日本内分泌学会(JES)发布了自身免疫性和IgG4相关性垂体炎的诊断和治疗指南，吹体验常伴有垂体功能障碍，依据病因、组织学和炎症在垂体中的部位可分为几种亚型。本文主要针对自身免疫性和IgG4相关性垂体炎的诊断和治疗提供指导建议。

 

拓展指南：与自身免疫相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2020 JES临床指南：自身免疫性和IgG4相关性垂体炎的诊断和治疗)] GetToolGuiderByIdResponse(projectId=1, id=35f161c00186a601, title=2020 JES临床指南：自身免疫性和IgG4相关性垂体炎的诊断和治疗, enTitle=Diagnosis and treatment of autoimmune and IgG4- related hypophysitis: clinical guidelines of the Japan Endocrine Society, guiderFrom=Endocr J. 2020 Feb 7., authorId=null, author=, summary=2020年2月，日本内分泌学会(JES)发布了自身免疫性和IgG4相关性垂体炎的诊断和治疗指南，吹体验常伴有垂体功能障碍，依据病因、组织学和炎症在垂体中的部位可分为几种亚型。本文主要针对自身免疫性和IgG4相关性垂体炎的诊断和治疗提供指导建议。 , cover=, journalId=null, articlesId=null, associationId=1876, associationName=日本内分泌学会, associationIntro= , copyright=0, guiderPublishedTime=Fri Feb 07 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<P>2020年2月，日本内分泌学会(JES)发布了自身免疫性和IgG4相关性垂体炎的诊断和治疗指南，吹体验常伴有垂体功能障碍，依据病因、组织学和炎症在垂体中的部位可分为几种亚型。本文主要针对自身免疫性和IgG4相关性垂体炎的诊断和治疗提供指导建议。 </P> <P> </P>拓展指南：<STRONG>与<FONT color=red>自身免疫</FONT>相关指南：</STRONG><BR> <UL> <LI><A title="2019 AASLD实践指南：成人和儿童自身免疫性肝炎的诊断和治疗" target=_blank href="//m.sandwebs.com/guideline/show_article.do?id=f8ae01c0018a45fd">2019 AASLD实践指南：成人和儿童自身免疫性肝炎的诊断和治疗</A> <LI><A title="2019 意大利建议：成人自身免疫性风湿病患者流感和肺炎球菌疫苗接种" target=_blank href="//m.sandwebs.com/guideline/show_article.do?id=9dd151c001e91989">2019 意大利建议：成人自身免疫性风湿病患者流感和肺炎球菌疫苗接种</A> <LI><A title=吗替麦考酚酯在自身免疫病治疗中应用的风湿病专家共识 target=_blank href="//m.sandwebs.com/guideline/show_article.do?id=466ca1c001e86344">吗替麦考酚酯在自身免疫病治疗中应用的风湿病专家共识</A> <LI><A title="2019 EULAR建议：成人自身免疫性炎症性风湿性疾病的疫苗接种（更新版）" target=_blank href="//m.sandwebs.com/guideline/show_article.do?id=725b01c001e8a660">2019 EULAR建议：成人自身免疫性炎症性风湿性疾病的疫苗接种（更新版）</A> <LI><A title="2018 B细胞靶向治疗自身免疫性疾病继发性低丙种球蛋白血症的管理建议" target=_blank href="//m.sandwebs.com/guideline/show_article.do?id=d3bc81c001685644">2018 B细胞靶向治疗自身免疫性疾病继发性低丙种球蛋白血症的管理建议</A> 更多信息请点击：<A target=_blank href="//m.sandwebs.com/guideline/list.do?q=%E8%87%AA%E8%BA%AB%E5%85%8D%E7%96%AB">有关自身免疫更多指南</A></LI></UL>, tagList=[TagDto(tagId=99876, tagName=自身免疫性垂体炎), TagDto(tagId=99877, tagName=IgG4相关性垂体炎)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=15, categoryName=风湿免疫科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5331, appHits=271, showAppHits=10, pcHits=2335, showPcHits=4201, likes=26, shares=11, comments=5, approvalStatus=1, publishedTime=Tue Feb 18 15:23:03 CST 2020, publishedTimeString=2020-02-07, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Tue Feb 18 15:23:03 CST 2020, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 21:14:20 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2020 JES临床指南：自身免疫性和IgG4相关性垂体炎的诊断和治疗)])
2020 JES临床指南：自身免疫性和IgG4相关性垂体炎的诊断和治疗
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1189680, encodeId=652e1189680e2, content=认真学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ef96390311, createdName=ms3000000103982081, createdTime=Wed Feb 02 11:52:58 CST 2022, time=2022-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058133, encodeId=7a1c105813319, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5e82466251, createdName=1242a32cm95暂无昵称, createdTime=Wed Oct 06 16:12:24 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011629, encodeId=c8f1101162920, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Aug 26 09:20:37 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946897, encodeId=368994689e71, content=实用！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25e65432340, createdName=ms1000000432688292, createdTime=Tue Mar 09 20:48:14 CST 2021, time=2021-03-09, status=1, ipAttribution=)]
    2022-02-02 ms3000000103982081

    认真学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1189680, encodeId=652e1189680e2, content=认真学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ef96390311, createdName=ms3000000103982081, createdTime=Wed Feb 02 11:52:58 CST 2022, time=2022-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058133, encodeId=7a1c105813319, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5e82466251, createdName=1242a32cm95暂无昵称, createdTime=Wed Oct 06 16:12:24 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011629, encodeId=c8f1101162920, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Aug 26 09:20:37 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946897, encodeId=368994689e71, content=实用！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25e65432340, createdName=ms1000000432688292, createdTime=Tue Mar 09 20:48:14 CST 2021, time=2021-03-09, status=1, ipAttribution=)]
    2021-10-06 1242a32cm95暂无昵称

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1189680, encodeId=652e1189680e2, content=认真学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ef96390311, createdName=ms3000000103982081, createdTime=Wed Feb 02 11:52:58 CST 2022, time=2022-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058133, encodeId=7a1c105813319, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5e82466251, createdName=1242a32cm95暂无昵称, createdTime=Wed Oct 06 16:12:24 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011629, encodeId=c8f1101162920, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Aug 26 09:20:37 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946897, encodeId=368994689e71, content=实用！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25e65432340, createdName=ms1000000432688292, createdTime=Tue Mar 09 20:48:14 CST 2021, time=2021-03-09, status=1, ipAttribution=)]
    2021-08-26 未来将来

    不错不错

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1189680, encodeId=652e1189680e2, content=认真学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ef96390311, createdName=ms3000000103982081, createdTime=Wed Feb 02 11:52:58 CST 2022, time=2022-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058133, encodeId=7a1c105813319, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5e82466251, createdName=1242a32cm95暂无昵称, createdTime=Wed Oct 06 16:12:24 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011629, encodeId=c8f1101162920, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Aug 26 09:20:37 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946897, encodeId=368994689e71, content=实用！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25e65432340, createdName=ms1000000432688292, createdTime=Tue Mar 09 20:48:14 CST 2021, time=2021-03-09, status=1, ipAttribution=)]
    2021-03-09 ms1000000432688292

    实用！

    0

Baidu
map
Baidu
map
Baidu
map